Home » Topics » BioWorld Science

BioWorld Science
RSS

First patient dosed in phase I/II study of the bicycle toxin conjugate BT-5528

Nov. 14, 2019

Results from multiple phase III studies of anemia treatment roxadustat presented

Nov. 14, 2019

Mouse-human chimeric anti-CXADR antibody shows antitumor activity in prostate and SCLC models

Nov. 14, 2019

First-in-class fusion inhibitor against diverse and multidrug-resistant HCV strains presented

Nov. 14, 2019

SHR-4640: a potential new hyperuricemia treatment option

Nov. 14, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

TFEB initiates fat cell browning

Nov. 14, 2019

Bellerophon reports initial data from acute hemodynamic study of INOpulse

Nov. 13, 2019

New exploratory phase I/II study in Japan assesses NS-089 in Duchenne muscular dystrophy

Nov. 13, 2019

Break out the sparkling apple cider for DUR-928 alcoholic hepatitis data

Nov. 13, 2019

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...